Skip to Content

University of Colorado Boulder
Venture Partners at CU Boulder

Main menu

  • Home
  • Get Started
  • About Us
  • What We Do
  • News
  • Blog
  • Events
  • Contact Us
University of Colorado Boulder
Search

Search

Other ways to search:

  • Events Calendar
  • Campus Map
Venture Partners at CU Boulder
Venture Partners at CU Boulder

Main menu

  • Home
  • Get Started
  • About Us
  • What We Do
  • News
  • Blog
  • Events
  • Contact Us

Secondary Menu

  • Disclose Your Invention Online
  • Join Our Email List
  • Research & Innovation Office

Mobile menu

  • Home
  • Get Started
  • About Us
  • What We Do
  • News
  • Blog
  • Events
  • Contact Us
  • Disclose Your Invention Online
  • Join Our Email List
  • Research & Innovation Office

COVID-19 Innovations

COVID-19 Innovations

Venture Partners at CU Boulder is identifying new innovations that address problems related to the COVID-19 pandemic. 

Browse our innovations available for licensing and our startups looking for partnerships.

Innovations Available for Licensing

To ensure that CU Boulder innovations pertaining to COVID-19 are rapidly brought to those who need them most, Venture Partners will be adopting an “Open Access” licensing strategy. This means that patent rights for these innovations will be available for free during the pandemic, under a simple click-through license, and software will be made accessible through open source licensing. Other licensing models will also be adopted, as needed, where preferred partners require exclusivity.

ding lab

Acousto Thermal Shift Assay for Rapid and Cost-Efficient Diagnosis of COVID-19

The technology could be applied to fast diagnosis in hospitals or point of care applications for many infectious diseases including the diagnosis of COVID-19 or SARS-CoV-2 virus.

Contact Nicole Forsberg

hernandez lab

Peroxide Enhanced Germicidal Irradiation (PEGI)

Researchers at CU Boulder—led by Professor Mark Hernandez—have developed Peroxide Enhanced Germicidal Irradiation (PEGI), a new method for sanitizing indoor air that takes advantage of both the disinfection characteristics of UV as well as its interaction with peroxide, effectively expanding the reliability and “reach” of its disinfection capabilities.

Contact Nicole Forsberg

Startups Looking for Partnerships

Several of our CU Boulder startups are looking to advance their innovations, but are in need of specific resources in order to bring their products to market.

sick stick graphic

Darwin Biosciences

All COVID-19 diagnostics currently being used detect biomolecules indicating infection after it’s too late, but Darwin Biosciences has developed SickStick, a diagnostic test that knows you’re sick before you do. The company offers two saliva-based solutions, one ready now for confirmatory testing that’s lab based (CoVScreen), and one requiring additional resources to accelerate its development (CoVStick). The company is in need of resources for aggressive acceleration of product release:

  • COVID-19 samples in any biospecimen form — enables confirmatory testing within days
  • Clinical trial site(s) to execute protocol and determine sensitivity and specificity
  • Capital and partners to achieve our six month goals

Contact CEO Nick Meyerson at nrmeyerson@gmail.com and COO Rick Whitcomb at rick@rickwhitcomb.com for SickStick inquiries.

Check Out This Story

bcell solutions graph

BCell Solutions, Inc.

BCell Solutions, Inc., a pre-clinical stage biopharmaceutical company, is assessing use of its peptide immunotherapies as a potential therapeutic intervention to assist late-stage, critically ill COVID-19 patients. It’s BCS-N01 immunotherapy appears effective in blockading pro-inflammatory cytokines IL-1B and IL-6, which appear centrally involved in lethal hyper-inflammation (such as virus-induced sepsis) associated with end stage organ failure in COVID-19 patients. The company is seeking industry collaboration and funding to support their COVID efforts. 

Contact CEO Chip Landman at cl@watersolve.com for B Cell related inquiries.

vaccines

VitriVax

VitriVax has developed a vaccine formulation platform that enables thermostability, extended shelf life, and combined doses in a single injection, for virtually any vaccine. The company is currently working on a pilot-scale system capable of producing 10,000 to 100,000 doses of COVID-19 vaccines per run that would be ready for use as human trials of vaccines begin in the next year. The company is looking for investment, grant funding, and partners with COVID vaccine candidates that could benefit from thermostability and combining prime and boost doses into a single injection.

Contact CEO Matt Raider at mraider@vitrivaxbio.com for VitriVax related inquiries.

Check Out This Story

new iridium team

New Iridium

New Iridium, a company developing commercialized photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $256,000 to conduct research and development work on facilitating timely availability of Remdesivir, a potential life-saving drug in the global fight against COVID-19. This grant funds the development of an optimized manufacturing process for Remdesivir that utilizes photocatalysis, a powerful new chemical technology driven by light rather than heat. If successful, the new process will result in shortened production times and higher yields, providing greater supply to the market more quickly than current manufacturing protocols. 

Contact CEO and founder Chern-Hooi Lim at chern@newiridium.com for New Iridium related inquiries.

Read the Press Release

Connect With Us

  • LinkedIn
  • Twitter
  • YouTube

Join Our Email List

Subscribe

Disclose Your Invention Online

Fill Out The Form

Venture Partners at CU Boulder

4845 Pearl East Circle, Suite 300
588 UCB
Boulder, CO 80309
vpcontact@colorado.edu
Fax: 303-860-6211

University of Colorado Boulder

University of Colorado Boulder
© Regents of the University of Colorado
Privacy • Legal & Trademarks • Campus Map

Return to the top of the page